Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CDX-011

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Denise A. Yardley, MD1, Michelle E. Melisko, MD2, Andres Forero, MD3, Brooke R. Daniel, MD4, Alberto J. Montero, MD, MBA5, Troy H… Expand
Is this relevant?
2016
2016
Purpose: To determine if BRAF and/or MEK inhibitor–induced GPNMB expression renders melanomas sensitive to CDX-011, an antibody… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
TPS1110 Background: The internalizable transmembrane glycoprotein NMB (gpNMB) is overexpressed in 20% of BC, including 40% of… Expand
Is this relevant?
2014
2014
BACKGROUND Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein… Expand
Is this relevant?
Review
2014
Review
2014
Exploiting the highly targeted nature of monoclonal antibodies to deliver selectively to tumor cells a cytotoxic payload is an… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2013
2013
The development of monoclonal antibodies as cancer therapeutic agents has improved the outlook for many patients as evidenced by… Expand
Is this relevant?
2012
2012
Background: GPNMB is an internalizable transmembrane glycoprotein overexpressed in multiple tumor types, including breast cancer… Expand
Is this relevant?
2011
2011
The World Antibody Drug Conjugate Summit Europe, organized by Biorbis/ Hanson Wade was held in Frankfurt, Germany on February 21… Expand
Is this relevant?
2010
2010
8525 Background: CDX-011 is an ADC consisting of the potent cellular toxin MMAE conjugated to a fully human monoclonal antibody… Expand
Is this relevant?
2010
2010
1095 Background: GPNMB (osteoactivin), a novel glycoprotein expressed in 25-40% of breast cancers as well as various tumor types… Expand
Is this relevant?